6.59 USD
+0.47 (+7.68%)
We assign a fundamental rating of 1 out of 10 to ARMP. ARMP was compared to 525 industry peers in the Biotechnology industry. ARMP has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, ARMP is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
- In the past year ARMP has reported negative net income.
- In the past year ARMP has reported a negative cash flow from operations.
- ARMP had negative earnings in each of the past 5 years.
- In the past 5 years ARMP always reported negative operating cash flow.
1.2 Ratios
- With a decent Return On Assets value of -31.82%, ARMP is doing good in the industry, outperforming 65.52% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -31.82% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-43.53%
ROA(5y)-43.98%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- ARMP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- ARMP does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for ARMP remains at a similar level compared to 1 year ago.
- ARMP has more shares outstanding than it did 5 years ago.
- ARMP has a worse debt/assets ratio than last year.
2.2 Solvency
- ARMP has an Altman-Z score of -8.22. This is a bad value and indicates that ARMP is not financially healthy and even has some risk of bankruptcy.
- With a Altman-Z score value of -8.22, ARMP is not doing good in the industry: 68.38% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -8.22 |
ROIC/WACCN/A
WACC8.37%
2.3 Liquidity
- ARMP has a Current Ratio of 0.06. This is a bad value and indicates that ARMP is not financially healthy enough and could expect problems in meeting its short term obligations.
- The Current ratio of ARMP (0.06) is worse than 94.86% of its industry peers.
- ARMP has a Quick Ratio of 0.06. This is a bad value and indicates that ARMP is not financially healthy enough and could expect problems in meeting its short term obligations.
- The Quick ratio of ARMP (0.06) is worse than 94.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.06 | ||
| Quick Ratio | 0.06 |
3. Growth
3.1 Past
- The earnings per share for ARMP have decreased strongly by -15.79% in the last year.
- The Revenue has grown by 14.24% in the past year. This is quite good.
- The Revenue has been growing slightly by 5.00% on average over the past years.
EPS 1Y (TTM)-15.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-393.33%
Revenue 1Y (TTM)14.24%
Revenue growth 3Y5%
Revenue growth 5YN/A
Sales Q2Q%-61.02%
3.2 Future
- The Earnings Per Share is expected to grow by 16.20% on average over the next years. This is quite good.
- Based on estimates for the next years, ARMP will show a very strong growth in Revenue. The Revenue will grow by 78.86% on average per year.
EPS Next Y-220.71%
EPS Next 2Y-46.22%
EPS Next 3Y-35.2%
EPS Next 5Y16.2%
Revenue Next Year-3.64%
Revenue Next 2Y-41.42%
Revenue Next 3Y3.46%
Revenue Next 5Y78.86%
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for ARMP. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ARMP. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- ARMP's earnings are expected to decrease with -35.20% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-46.22%
EPS Next 3Y-35.2%
5. Dividend
5.1 Amount
- No dividends for ARMP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
ARMATA PHARMACEUTICALS INC / ARMP FAQ
What is the ChartMill fundamental rating of ARMATA PHARMACEUTICALS INC (ARMP) stock?
ChartMill assigns a fundamental rating of 1 / 10 to ARMP.
What is the valuation status for ARMP stock?
ChartMill assigns a valuation rating of 0 / 10 to ARMATA PHARMACEUTICALS INC (ARMP). This can be considered as Overvalued.
How profitable is ARMATA PHARMACEUTICALS INC (ARMP) stock?
ARMATA PHARMACEUTICALS INC (ARMP) has a profitability rating of 1 / 10.
What is the financial health of ARMATA PHARMACEUTICALS INC (ARMP) stock?
The financial health rating of ARMATA PHARMACEUTICALS INC (ARMP) is 0 / 10.
Can you provide the expected EPS growth for ARMP stock?
The Earnings per Share (EPS) of ARMATA PHARMACEUTICALS INC (ARMP) is expected to decline by -220.71% in the next year.